Skip to main content Accessibility help
×
Home

Bevacizumab Use for Recurrent High-Grade Glioma at McGill University Hospital

  • Solmaz Sahebjam (a1), Evgenia Garoufalis (a2), Marie-Christine Guiot (a3), Thierry Muanza (a4), Rolando Del Maestro (a5), Kevin Petrecca (a5), Rajesh Sharma (a2) and Petr Kavan (a2)...

Abstract

Background:

Bevacizumab, a humanized recombinant anti-vascular endothelial growth factor antibody, was approved in Canada in 2010 for the treatment of high-grade glioma. We report the effectiveness and safety of bevacizumab in the treatment of patients with recurrent high-grade gliomas at a single institution.

Methods:

Twenty-seven consecutive patients with high-grade glioma (anaplastic glioma and glioblastoma) at first or subsequent relapse were treated with bevacizumab alone or in combination with chemotherapy. The primary endpoint was progression-free survival (PFS) and secondary endpoints were objective response rate, six month PFS, overall survival (OS), and safety profile.

Results:

The clinical benefit rate (complete and partial responses plus stable disease) was 59%. Median PFS was 4.3 (95% CI, 3.0-10.9) months, with a six month PFS rate of 43%. Median OS after current relapse was 8.9 (95% CI, 5.8-not reached) months. Ten episodes of grade 3/4 adverse events were observed in nine patients, including fatigue (n = 3), thrombocytopenia (n = 4), and myelotoxicity, febrile neutropenia, and pulmonary embolism (each n = 1).

Conclusions:

We consider the efficacy and safety profile of bevacizumab is comparable to other cohorts of patients treated for recurrent high-grade glioma at other international institutions.

Résumé: Contexte:

Le bevacizumab, un anticorps recombinant humanisé dirigé contre le facteur de croissance endothélial vasculaire, a été approuvé au Canada en 2010 pour le traitement du gliome de haut grade de malignité. Nous rapportons l'efficacité et la sécurité du bevacizumab dans le traitement de patients présentant une récidive de gliomes de haut grade de malignité dans notre institution.

Méthode:

Vingt-sept patients consécutifs atteints de gliomes de haut grade de malignité (gliomes anaplasiques et glioblastomes) ont été traités par le bevacizumab seul ou en combinaison à la chimiothérapie à la première récidive ou au moment de récidives subséquentes. le critère d'évaluation primaire était la survie sans progression (SSP) et les critères d'évaluation secondaires étaient le taux de réponse objective, une SSP de 6 mois, la survie globale (SG), et le profil de sécurité.

Résultats:

Le taux de bénéfice clinique (réponse complète et partielle avec maladie stable) était de 59%. la SSP médiane était de 4,3 mois (IC à 95%: 3,0 à 10,9) avec un taux de SSP de 6 mois de 43%. la SG médiane après la récidive en cours était de 8,9 mois (IC à 95% de 5,8 à non atteinte). Dix épisodes d'incidents thérapeutiques de grade ¾ ont été observés chez 9 patients, dont de la fatigue (n = 3), une thrombocytopénie (n = 4) et une myélotoxicité, une neutropénie fébrile et une embolie pulmonaire (n = 1 chacun).

Conclusions:

Nous considérons que le profil d'efficacité et de sécurité du bevacizumab que nous avons observé est comparable à celui d'autres cohortes de patients traités pour une récidive d'un gliome de haut grade de malignité dans d'autres institutions internationales.

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Bevacizumab Use for Recurrent High-Grade Glioma at McGill University Hospital
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Bevacizumab Use for Recurrent High-Grade Glioma at McGill University Hospital
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Bevacizumab Use for Recurrent High-Grade Glioma at McGill University Hospital
      Available formats
      ×

Copyright

Corresponding author

McGill University, Royal Victoria Hospital, Department of Oncology, 687 Pine avenue West, Montreal, Quebec, H3a 1a1, Canada. Email: petr.kavan@mcgill.ca.

References

Hide All
1. Adamson, C, Kanu, OO, Mehta, AI, et al. Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opin Investig Drugs. 2009;18(8):106183.
2. Stupp, R, Mason, WP, van den Bent, MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.
3. Curran, WJ Jr, Scott, CB, Horton, J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993;85(9):704–10.
4. Kargiotis, O, Rao, JS, Kyritsis, AP. Mechanisms of angiogenesis in gliomas. J Neurooncol. 2006;78(3):281–93.
5. Ferrara, N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25(4):581611.
6. Hicklin, DJ, Ellis, LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23(5):1011–127.
7. Gerber, HP, Ferrara, N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 2005;65(3):671–80.
8. Yang, JC, Haworth, L, Sherry, RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349(5):427–34.
9. Hurwitz, H, Fehrenbacher, L, Novotny, W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):233542.
10. Sandler, A, Gray, R, Perry, MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):254250.
11. Miller, K, Wang, M, Gralow, J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):266676.
12. Mathieu, V, De Néve, N, Le Mercier, M, et al. Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. Neoplasia. 2008;10(12):138392.
13. Lee, CG, Heijn, M, di Tomaso, E, et al. Anti-vascular endothelial growth factor treatment augments tumour radiation response under normoxic or hypoxic conditions. Cancer Res. 2000;60(19):556570.
14. Vredenburgh, JJ, Desjardins, A, Herndon, JE 2nd, et al: Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007a;13(4):1253–9.
15. Vredenburgh, JJ, Desjardins, A, Herndon, JE 2nd, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007b;25(30):4722–9.
16. Norden, AD, Young, GS, Setayesh, K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008;70(10):779–87.
17. Kreisl, TN, Kim, L, Moore, K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27(5):7405.
18. Friedman, HS, Prados, MD, Wen, PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):473340.
19. Cohen, MH, Shen, YL, Keegan, P, Pazdur, R. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist. 2009;14(11):1131–8.
20. Wen, PY, Macdonald, DR, Reardon, DA, et al. Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):196372.
21. Theeler, BJ, Groves, MD. High-grade gliomas. Curr Treat Options Neurol. 2011;13(4):386–99.
22. Yung, WK, Albright, RE, Olson, J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000;83(5):588–93.
23. Wong, ET, Gautam, S, Malchow, C, Lun, M, Pan, E, Brem, S. Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis. J Natl Compr Canc Netw. 2011;9(4):4037.
24. Poulsen, HS, Grunnet, K, Sorensen, M, et al. Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours. Acta Oncol. 2009;48(1):52–8.
25. Soffietti, R, Ruda, R, Trevisan, E, et al. Phase II study of bevacizumab and nitrosourea in patients with recurrent malignant glioma: a multicenter Italian study. J Clin Oncol. 2009;27(suppl; abstr 2012).
26. Reardon, DA, Desjardins, A, Vredenburgh, JJ, et al. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. Br J Cancer. 2009;101(12):198694.
27. Guiu, S, Taillibert, S, Chinot, O, et al. Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study. Rev Neurol (Paris). 2008;164(6-7):588–94.
28. Gilbert, MR, Wang, M, Aldape, K, et al. RTOG 0625: a phase II study of bevacizumab with irinotecan in recurrent glioblastoma (GBM). J Clin Oncol. 2009;27(suppl; abstr 2011).
29. Sathornsumetee, S, Desjardins, A, Vredenburgh, JJ, et al. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol. 2010;12(12):130010.
30. Verhoeff, JJ, Lavini, C, van Linde, ME, et al. Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma. Ann Oncol. 2010;21(8):1723–7.
31. Elandt, K, Preusser, M, Hassler, M, et al. Treatment with bevacizumab and liposomal doxorubicin for recurrent high-grade gliomas (HGGs). J Clin Oncol. 2010;28(suppl; abstr e12522).
32. Calabrich, A, Azevedo, FC, Saad, ED, et al. The feasibility and real-life effectiveness of the combination of chemotherapy (CT) and bevacizumab (Bev) in the treatment of high-grade gliomas (HGG) in a private community oncology center. J Clin Oncol. 2010;28(suppl; abstr e12552).
33. Gallardo Martin, E, Areses Manrique, MC, Anido Herranz, U, et al. Efficacy, toxicity, and pattern of response and progression in patients with high-grade gliomas treated with bevacizumab and irinotecan: experience in one center. J Clin Oncol. 2010;28 (suppl; abstr e12553).
34. Vredenburgh, JJ, Coughesy, T, Samant, M, et al. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist. 2010;15(12):132934.
35. Henriksson, R, Asklund, T, Poulsen, HS. Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review. J Neurooncol. 2011;104(3):639–46.

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed